BioSpace News Archive

SMSbiotech, a privately held biotech pioneer, has engaged the national investment banking firm, Exemplar Capital, for the purposes of strategic advisory services and capital raising.

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the pricing of its upsized initial public offering of 9.6 million shares of common stock at a public offering price of $19 per share

Arcutis Biotherapeutics, Inc. announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $25.00 per share, before underwriting discounts and commissions.